The recent Fuji-Xerox deal made headlines for all the wrong reasons.
US partners Peter Lyons, Matthew Herman and Linda Martin, along with associate Marissa Yu, take a look at what happened – and what the takeaways are for your next major transaction.
No Worse Off #6: Liability management
Essential Antitrust #41: Vertical restraints enforcement: trends to watch
Navigating Cybersecurity Risks in the Healthcare Sector
Episode #2: EU elections - A business outlook
No Worse Off #5: Cross-border restructurings
Essential Antitrust #40: America’s impending outbound investment controls: what investors need to know
Managing Risk in Asia #9: Southeast Asia – time to shine?
Reward(ing) Half Hour: Episode 3 Next Stop: CSOP
Reward(ing) Half Hour: Episode 2 Remuneration vs Compensation – the Transatlantic Pay Debate
No Worse Off #4: Richard Tett, 30 years in restructuring
Essential Antitrust #39: UK in-depth merger reviews: new process adopted by the CMA
No Worse Off #3: UK Restructuring Plans – Relevant Alternative, timetabling and jurisdiction
No Worse Off #2: After the battles, a coming of age for the UK restructuring plan?
Reward(ing) Half Hour: Being prepared for the (not so) unexpected: planning for executive exits
Tax Matters: Spring Budget 2024 – The Hunt for Blue October
No Worse Off #1: Overview of current restructuring trends
Essential Antitrust #38: What businesses can expect from China’s revised merger control regime
Impressions from the J.P. Morgan Healthcare Conference – A MedTech Perspective
Essential Antitrust #37: Antitrust in 2024: competition enforcement takes center stage
Legends of Tech #1: Turing with Vint and Whit: Boris Feldman in conversation with Vinton G. Cerf and Whitfield Diffie
Create your
podcast in
minutes
It is Free
The emPOWERed Half Hour
Bank of America Treasury Insights
How I Crushed It
Pharmacy Podcast Network
The Ramsey Show
Planet Money